Micro Cap Biotech Secures $60M to Advance Alzheimer’s Treatment, Shares Surge
Alzheimer’s disease is the most common form of dementia, primarily affecting people over the age of 65. It progressively damages brain cells through the buildup of abnormal proteins (known as plaques and tangles) which destroy neurons and interfere with communication throughout the brain.Developing effective prevention or treatment remains extremely challenging because Alzheimer’s is driven by multiple interacting factors, including inflammation, genetics, and possibly infections, rather than a single cause. In addition, many therapies struggle to reach the brain due to its ...